Position in KYMR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,251,578
+$1,138,822 QoQ
Shares Held
27,033
+37.5% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.60%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KYMR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Neo Ivy Capital Management holds $22,354,354 across 16 Biotechnology names. KYMR ranks #4 (10.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DYN |
Dyne Therapeutics, Inc.
|
168,753 | $3,059,491 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
186,172 | $2,692,047 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
43,355 | $2,449,123 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
This page
|
27,033 | $2,251,578 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
60,833 | $2,020,872 | |
| 6 | ADMA |
Adma Biologics, Inc.
|
199,687 | $1,799,179 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
64,106 | $1,775,736 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
73,601 | $1,541,940 |
All Filings in KYMR
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,251,578 | 27,033 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $1,112,756 | 19,660 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $894,576 | 20,499 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $394,675 | 14,420 | Shares | Sole | 2025-05-06 | |
| No filing history on record for this holder in this stock. | ||||||